<DOC>
	<DOCNO>NCT01739322</DOCNO>
	<brief_summary>The objective study determine biologic activity Platanus acerifolia allergen extract histamine equivalent prick ( HEP ) unit , order use in-house reference preparation ( IHRP ) .</brief_summary>
	<brief_title>Biological Standardization Platanus Acerifolia Allergen Extract</brief_title>
	<detailed_description>This open , unblinded non-randomized biological assay . The study design slight modification recommendation propose Nordic Guidelines . Four concentration Platanus acerifolia allergen extract , together positive negative control , use 10 mg/ml histamine dihydrochloride solution glycerinated phenol saline solution , respectively , test every patient duplicate volar surface forearm .</detailed_description>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<criteria>Subject provide write informed consent , appropriately sign date subject ( legal representative , applicable ) . Subject male female race ethnic group . Age &gt; =18 year &lt; =60 year study inclusion day . Positive skin prick test standardize commercially available preparation Platanus acerifolia allergen extract . The skin prick test consider positive test result wheal major diameter least 3 mm area least 7 mm2 . Positive skin prick test result valid perform within one year prior inclusion subject study A positive test specific IgE Platanus acerifolia ( CAPRAST major equal 2 ) . IgE result valid perform within oneyear prior inclusion subject study . Allergic symptoms pollen season Platanus acerifolia . Medical history positive allergy inhalation ( rhinitis /or rhinoconjunctivitis and/or asthma ) Platanus acerifolia . Immunotherapy past 5 year allergen preparation know interfere allergen test due high degree crossreactivity ( example : specie Platanus : Platanus orientalis , Platanus occidentalis ) . Use drug may interfere skin reaction ( e.g. , antihistamine ) . See Appendix 1 protocol . Treatment follow medication : oral tricyclic tetracyclic antidepressant IMAOs , betablockers , chronic use corticosteroid use oral parenteral corticosteroid repeat intermittent pattern ( 10 mg/daily prednisone equivalent ) . Women pregnant period breastfeed woman pregnancy test positive visit 2 , prior prick test . Dermographism affect skin area test site either study visit . Atopic dermatitis affect skin area test site either study visit . Urticaria affect skin area test site either study visit . Diseases immune system relevant clinically , autoimmune immunodeficiency . Serious disease control may increase risk safety subject involve study , include , limited following : heart failure , uncontrolled severe respiratory disease , endocrine disease , clinically relevant kidney liver diseases hematological disease . Participation clinical trial within 30 day ( 5 time biological halflife research study product , whichever long ) prior inclusion subject clinical trial . Patients diseases condition limit use adrenaline ( heart disease , severe hypertension , .. ) Severe psychiatric , psychological neurological disorder Abuse alcohol , drug medicine previous year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>